FY2025 EPS Estimates for DENTSPLY SIRONA Lifted by Analyst

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Stock analysts at Barrington Research boosted their FY2025 EPS estimates for shares of DENTSPLY SIRONA in a note issued to investors on Monday, May 12th. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will post earnings per share of $1.90 for the year, up from their prior estimate of $1.86. Barrington Research currently has a “Outperform” rating and a $21.00 target price on the stock. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.84 per share. Barrington Research also issued estimates for DENTSPLY SIRONA’s FY2026 earnings at $2.10 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 EPS for the quarter, topping the consensus estimate of $0.29 by $0.14. DENTSPLY SIRONA had a negative net margin of 10.59% and a positive return on equity of 12.62%. The firm had revenue of $879.00 million for the quarter, compared to the consensus estimate of $854.75 million. During the same period in the prior year, the business posted $0.42 earnings per share. The business’s quarterly revenue was down 7.8% on a year-over-year basis.

XRAY has been the subject of a number of other research reports. Robert W. Baird decreased their target price on DENTSPLY SIRONA from $22.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday, February 28th. Jefferies Financial Group downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating and dropped their target price for the stock from $30.00 to $20.00 in a report on Thursday, January 23rd. StockNews.com upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research note on Friday, May 9th. Needham & Company LLC restated a “hold” rating on shares of DENTSPLY SIRONA in a research note on Thursday, March 13th. Finally, Mizuho lowered their target price on DENTSPLY SIRONA from $21.00 to $18.00 and set a “neutral” rating on the stock in a report on Thursday, March 13th. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $20.36.

DENTSPLY SIRONA Stock Performance

XRAY opened at $16.45 on Wednesday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.84 and a current ratio of 1.25. The company has a market cap of $3.28 billion, a PE ratio of -7.95, a price-to-earnings-growth ratio of 1.80 and a beta of 0.92. The stock has a 50-day moving average of $14.38 and a 200-day moving average of $17.48. DENTSPLY SIRONA has a 52-week low of $12.16 and a 52-week high of $28.50.

DENTSPLY SIRONA Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, April 11th. Stockholders of record on Friday, March 28th were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 3.89%. The ex-dividend date was Friday, March 28th. DENTSPLY SIRONA’s payout ratio is -14.10%.

Insider Buying and Selling

In related news, Director Gregory T. Lucier bought 15,142 shares of DENTSPLY SIRONA stock in a transaction on Monday, March 3rd. The shares were purchased at an average price of $16.51 per share, for a total transaction of $249,994.42. Following the completion of the acquisition, the director now owns 81,971 shares in the company, valued at approximately $1,353,341.21. This represents a 22.66% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On DENTSPLY SIRONA

Institutional investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. boosted its stake in shares of DENTSPLY SIRONA by 15,105.1% during the 4th quarter. Pacer Advisors Inc. now owns 4,503,591 shares of the medical instruments supplier’s stock worth $85,478,000 after buying an additional 4,473,972 shares during the last quarter. Nuance Investments LLC boosted its position in DENTSPLY SIRONA by 25.0% during the fourth quarter. Nuance Investments LLC now owns 13,545,981 shares of the medical instruments supplier’s stock valued at $257,103,000 after purchasing an additional 2,708,097 shares during the last quarter. Norges Bank bought a new position in DENTSPLY SIRONA in the fourth quarter valued at approximately $45,730,000. AQR Capital Management LLC increased its position in shares of DENTSPLY SIRONA by 245.1% during the 4th quarter. AQR Capital Management LLC now owns 2,893,023 shares of the medical instruments supplier’s stock worth $54,389,000 after purchasing an additional 2,054,767 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of DENTSPLY SIRONA by 18.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,549,242 shares of the medical instruments supplier’s stock worth $238,186,000 after purchasing an additional 1,975,404 shares in the last quarter. 95.70% of the stock is owned by institutional investors.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.